Related Experiment Video
Updated: May 25, 2025
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer
Patricia Lara1, Araceli Aguilar-González2,3, Francisco Martín2,4,5
1Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.
Background:
Lung cancer is a leading cause of cancer-related deaths worldwide. Its high incidence and poor prognosis demonstrate the need to investigate new therapies. The PI3K/AKT pathway is activated in carcinogenic processes such as invasion, proliferation, and drug resistance. MiR-21 is a microRNA overexpressed in numerous types of cancer and which activates PI3K/AKT pathway by down-regulating its main targets, PTEN and PDCD4. CRISPR is a revolutionary gene-editing technology that allows genes to be deleted. The aim of this study was to use CRISPR/Cas9 technology as an option to reduce carcinogenic and drug resistance processes by eliminating miR-21.
Methods:
CRISPR/Cas9 was used to knock out miR-21 (miR-21 KO) in A549 lung cancer cells and thus reverse the carcinogenic processes activated by miR-21 overexpression. Furthermore, the effect of miR-21 KO on drug resistance was studied, choosing the main chemotherapeutic agents used for the treatment of lung cancer: gemcitabine, carboplatin, paclitaxel, and oxaliplatin.
Results:
miR-21 KO A549 cells exhibited a reduction in proliferation, migration, and colony formation compared to A549 cells. In contrast, the expression of PTEN and PDCD4 increased in miR-21 KO A549 cells. Furthermore, miR-21 KO A549 cells showed a decrease in the IC50 of the drugs used for the treatment of lung cancer: gemcitabine, carboplatin, paclitaxel, and oxaliplatin.
Conclusions:
Based on these results, miR-21 knock-out using CRISPR/Cas could be a promising strategy for the treatment of lung cancer.
Insights
Gene editing lung cancer cells by knocking out miR-21 (microRNA-21) reduced cancer growth and drug resistance. This CRISPR/Cas9 approach shows promise for new lung cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Gene Editing
Background:
- Lung cancer remains a leading cause of cancer mortality globally, necessitating novel therapeutic strategies.
- The PI3K/AKT pathway is crucial in cancer progression, with microRNA-21 (miR-21) overexpression activating this pathway by suppressing PTEN and PDCD4.
- CRISPR/Cas9 gene editing offers a method to target and delete specific genes, presenting a potential avenue for cancer treatment.
Purpose of the Study:
- To investigate the efficacy of CRISPR/Cas9 technology in eliminating miR-21 in lung cancer cells.
- To assess the impact of miR-21 knockout on cancer cell proliferation, migration, and drug resistance.
Main Methods:
- CRISPR/Cas9 gene editing was employed to generate miR-21 knockout (KO) A549 lung cancer cells.
- The study evaluated the effects of miR-21 KO on cell proliferation, migration, and colony formation.
- Drug resistance was assessed by measuring the IC50 of gemcitabine, carboplatin, paclitaxel, and oxaliplatin in miR-21 KO cells.
Main Results:
- miR-21 KO A549 cells demonstrated significantly reduced proliferation, migration, and colony formation.
- The expression of tumor suppressors PTEN and PDCD4 was upregulated in miR-21 KO cells.
- Knockout of miR-21 decreased the IC50 values for common lung cancer chemotherapeutics, indicating increased drug sensitivity.
Conclusions:
- miR-21 knockout via CRISPR/Cas9 technology is a potential therapeutic strategy for lung cancer.
- This approach may overcome drug resistance mechanisms in lung cancer treatment.
More Related Videos
07:52In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
Published on: November 2, 2020
07:01Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
Published on: May 2, 2025
